Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

The Tobias and Lechleiter families donated $20 million to establish the Institute for Clinical Innovation at IU Health, the ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...